Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Phenomenex inaugurates new head office in India
The new entity will serve research communities throughout India with sales and service teams that sell all Phenomenex products directly and provide timely technical support, training and seminars.
The new entity will serve research communities throughout India with sales and service teams that sell all Phenomenex products directly and provide timely technical support, training and seminars.
MorphoSys and OncoMed had entered into a license agreement in June 2006 to use MorphoSys’ HuCAL technology in the research and development of human therapeutic antibodies for the
The study is intended to establish if Multikine administered prior to current standard of care (Surgery plus Radiotherapy or Surgery plus Concurrent Radiochemotherapy) used for treatment naive subjects
Particle Sciences and Celanese EVA Performance Polymers are working to provide Particle Sciences with preferred access to VitalDose EVA polymer in early stage projects. Particle Sciences New Technologies
The company posted a net loss of $32.1m, or $0.57 per diluted share for the first quarter of 2011, compared to $34.08m, or $0.66 per diluted share, for
In clinical studies, Rasilamlo demonstrated reductions in blood pressure than Rasilez and amlodipine alone. The study results suggested that the use of single-pill combinations like Rasilamlo can provide
The US net sales increased 5% to $3.3bn in the first quarter of 2011 compared to the same period in 2010. International net sales increased 3%, or 1%
MediSpend is a secure hosted SaaS solution, which enables pharmaceutical, medical device, and biotechnology companies to track, aggregate, and report all spend data consistent with state and federal
For the first quarter of 2011, the company’s net income was EUR1.29bn, compared to EUR1.79bn in the prior year period. The company has generated gross profit of EUR5.83bn,
INNO-206 is intended to control the release of chemotherapeutic doxorubicin and to preferentially target tumors, which the company believes may make it more effective and less toxic in